Astrazeneca Complements Lung-cancer Franchise with New Licensing Deal

Dow Jones07-14 17:24

0923 GMT - AstraZeneca is moving to complement its lung-cancer franchise through a licensing deal of up to $1.5 billion for a drug from China's Dizal Pharmaceutical, analysts at J.P. Morgan say in a research note. The deal makes strategic sense for the U.K. drugmaker given that it brings in a new product that complements its existing Tagrisso franchise in lung cancer, the analysts say. Under the deal, AstraZeneca is acquiring worldwide rights to develop and commercialize Dizal's Zegfrovy, which is approved in the U.S. and China for the treatment of a type of advanced non-small cell lung cancer. Zegfrovy is under review by the FDA for approval as an initial treatment and would compete directly with Johnson & Johnson's Rybrevant as an oral, chemotherapy-free treatment option, the analysts add. AstraZeneca shares fall 1.1%.(adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 14, 2026 05:24 ET (09:24 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651847179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651847179","market":"fut","top_or_hot":-1,"title":"Astrazeneca Complements Lung-cancer Franchise with New Licensing Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0923 GMT - AstraZeneca is moving to complement its lung-cancer franchise through a licensing deal of up to $1.5 billion for a drug from China's Dizal Pharmaceutical, analysts at J.P. Morgan say in a research note. The deal makes strategic sense for the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker given that it brings in a new product that complements its existing Tagrisso franchise in lung cancer, the analysts say. Under the deal, AstraZeneca is acquiring worldwide rights to develop and commercialize Dizal's Zegfrovy, which is approved in the U.S. and China for the treatment of a type of advanced non-small cell lung cancer. Zegfrovy is under review by the FDA for approval as an initial treatment and would compete directly with Johnson &amp; Johnson's Rybrevant as an oral, chemotherapy-free treatment option, the analysts add. AstraZeneca shares fall 1.1%.(adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 05:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca Complements Lung-cancer Franchise with New Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca Complements Lung-cancer Franchise with New Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-14 17:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0923 GMT - AstraZeneca is moving to complement its lung-cancer franchise through a licensing deal of up to $1.5 billion for a drug from China's Dizal Pharmaceutical, analysts at J.P. Morgan say in a research note. The deal makes strategic sense for the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker given that it brings in a new product that complements its existing Tagrisso franchise in lung cancer, the analysts say. Under the deal, AstraZeneca is acquiring worldwide rights to develop and commercialize Dizal's Zegfrovy, which is approved in the U.S. and China for the treatment of a type of advanced non-small cell lung cancer. Zegfrovy is under review by the FDA for approval as an initial treatment and would compete directly with Johnson &amp; Johnson's Rybrevant as an oral, chemotherapy-free treatment option, the analysts add. AstraZeneca shares fall 1.1%.(adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 05:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651847179","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651847179","pubTimestamp":1784021040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0923 GMT - AstraZeneca is moving to complement its lung-cancer franchise through a licensing deal of up to $1.5 billion for a drug from China's Dizal Pharmaceutical, analysts at J.P. Morgan say in a research note. The deal makes strategic sense for the U.K. drugmaker given that it brings in a new product that complements its existing Tagrisso franchise in lung cancer, the analysts say. Under the deal, AstraZeneca is acquiring worldwide rights to develop and commercialize Dizal's Zegfrovy, which is approved in the U.S. and China for the treatment of a type of advanced non-small cell lung cancer. Zegfrovy is under review by the FDA for approval as an initial treatment and would compete directly with Johnson & Johnson's Rybrevant as an oral, chemotherapy-free treatment option, the analysts add. AstraZeneca shares fall 1.1%. Dow Jones NewswiresJuly 14, 2026 05:24 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688192":"迪哲医药-U","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","BK4588":"碎股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK0239":"医药制造","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","AZN":"阿斯利康","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC"},"translate_title":"阿斯利康通过新的许可协议补充肺癌特许经营权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688192":0.9,"AZN":0.9,"AZNH":0.6},"content_text":"0923 GMT - AstraZeneca is moving to complement its lung-cancer franchise through a licensing deal of up to $1.5 billion for a drug from China's Dizal Pharmaceutical, analysts at J.P. Morgan say in a research note. The deal makes strategic sense for the U.K. drugmaker given that it brings in a new product that complements its existing Tagrisso franchise in lung cancer, the analysts say. Under the deal, AstraZeneca is acquiring worldwide rights to develop and commercialize Dizal's Zegfrovy, which is approved in the U.S. and China for the treatment of a type of advanced non-small cell lung cancer. Zegfrovy is under review by the FDA for approval as an initial treatment and would compete directly with Johnson & Johnson's Rybrevant as an oral, chemotherapy-free treatment option, the analysts add. AstraZeneca shares fall 1.1%.(adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2026 05:24 ET (09:24 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651847179","isCrawlerRequest":true}